Biostem Technologies (BSEM) Centri Capital Conference 2025 summary

Company overview and recent performance

• Focuses on regenerative medicine using perinatal tissue for advanced wound care, with record revenue in 2024 exceeding $301 million and strong commercialization of AmnioWrap2 and VENDAJE AC.

• Operates a 6,000 sq ft CGTP and AATB-accredited facility in Pompano Beach, FL, with a market cap near $200 million and plans for a Nasdaq uplisting.

• Proprietary BioREtain processing preserves natural tissue properties, supporting superior product efficacy.

• Holds over 60 patents, including those for BioREtain and OxyCell technologies.

• Achieved EBITDA positivity and built a cash position of over $22 million by end of 2024.

Product portfolio and innovation

• Offers multiple products for wound and optic care, including AmnioWrap2, VENDAJE AC, VENDAJE (single-layer amnion), and VENDAJE OPTIC for ocular inflammation.

• Products leverage minimally manipulated tissue, retaining anti-inflammatory cytokines and long collagen strands for enhanced healing.

• Peer-reviewed publications support BioREtain's unique attributes.

• Four-year shelf life achieved through careful sterilization methods that preserve collagen structure.

• Exploring opportunities in cosmetics due to collagen properties, though regulatory pathways differ.

Commercial strategy and market expansion

• Commercialization primarily targets physician offices, mobile healthcare, long-term care, and skilled nursing, with plans to enter GPO and hospital contracts in 2025–2026.

• Partnership with Venture Medical as exclusive commercial arm, utilizing the Venture OneView platform and bona fide services to stabilize pricing and maintain ASP.

• Gained access to all seven Medicare MACs in 2024, driving significant revenue growth.

• No current GPO or hospital contracts, but expansion into these channels is a strategic priority.